Skip to main content
Figure 2 | Journal of Experimental & Clinical Cancer Research

Figure 2

From: Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial

Figure 2

Schematic overview of the administration system for 166Ho-RE.The administration system consists of the following components: iodine contrast agent (Visipaque ®, GE Healthcare) (1), saline solution (2), 20-ml syringe (Luer-Lock) (3), three-stopcock manifold (4), one-way valve (5), inlet line (6), administration vial containing the 166Ho-PLLA-MS (7), outlet line (8), flushing line (9), Y-connector (10) and catheter (11).

Back to article page